|
FDA Panel Recommends Arena’s Obesity Drug Lorcaserin
An agency advisory panel voted 18–4 with one abstention Thursday in favor of approval for Arena’s weight-loss drug lorcaserin.
This article is viewable by subscribers only. To view this article, please select an option below.
|
Subscribe
Archives